The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Key findings from the 2019-2020 National Lung Cancer Audit report
Neal Navani, MA, MRCP, MSc, PhD, Care Quality Improvement Department, Royal College of Physicians, London, UK, presents data from the annual National Lung Cancer Audit (NCLA) report, which analyzed data from patients diagnosed with lung cancer from 2019-2020. 1 year survival rates were at their highest in 2019, reflecting improvements in care, diagnosis and treatment. In 2020, the impact of the pandemic was seen, with less testing resulting in fewer reported incidences as well as less resection surgery being carried out. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Disclosures
Dr Navani has received honoraria for speaking, advisory boards or travel support from Amgen, Aidence, Astra Zeneca, Lilly, Takeda, Janssen, Merck, MSD, Pfizer, Oncimmune, PeerVoice, OncLive, Bristol-Meyers-Squibb and Olympus, as well as educational grants from Olympus, Cook Medical, Hitachi and Pentax.
